ACR Annual Meeting: In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: The use of methotrexate combined with or without the oral JAK inhibitor tofacitinib produced no clinically meaningful difference in 179 psoriatic arthritis patients from the OPAL Balance study, presented at ACR 2019 this week.
ACR Annual Meeting: More than half of survey psoriatic arthritis patients say they have adopted complementary or alternative medicine strategies and most say they've experienced some benefit, researchers reported November 12 at the annual meeting of the American College of Rheumatology in Atlanta.
ACR Annual Meeting: Compared with seven other biologics and a phosphodiesterase-4 inhibitor, the anti-IL-12/23 biologic ustekinumab was associated with a generally lower risk of serious infection requiring hospitalization in psoriasis or psoriatic arthritis patients, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.
ACR Annual Meeting: Intravenous golimumab produced lasting improvements in health-related quality of life for psoriatic arthritis patient one year post treatment, researchers reported on November 11 at the American College of Rheumatology annual meeting in Atlanta.
Secukinumab (Cosentyx, Novartis) provided sustained low rates of radiographic progression through 52 weeks in patients with active psoriatic arthritis, say researchers writing in Rheumatology this month.
Patients with psoriatic arthritis have twice the rate of joint surgery when compared with the general population, with one-third of patients with this condition undergoing joint surgery, say researchers writing in Annals of the Rheumatic Diseases this month.
Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.
A clinical trial presented at the Clinical Congress of Rheumatology West in San Diego last month shows that the oral JAK inhibitor tofacitinib improved the signs, symptoms and quality of life for patients with psoriatic arthritis who have not had an adequate response to DMARDs or TNF inhibitors.
Janssen is seeking FDA approval of guselkumab (Tremfya) for adults with active psoriatic arthritis. If approved, it would become the second IL-23 inhibitor in the U.S. market.